GlassScriptPhysician profile
Alexa Marie Thomas Deck
NPI 1750929295
$9,688.36
in general payments reported to CMS, 2019-2025
26 companies · $1,361 in 2025
The $1,361 reported for 2025 was more than what 85% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,440 · 2022: $1,741 · 2023: $2,548 · 2024: $2,598 · 2025: $1,361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,638 · Consulting Fee: $675 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,637.95 |
| Consulting Fee | $675.00 |
| Education | $193.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $1,667.92 | 2022-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $1,100.85 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $1,034.92 | 2022-2025 | Adbry, Anzupgo |
| Abbvie INC. | $915.03 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $628.61 | 2023-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $600.06 | 2021-2025 | Nemluvio, Epsolay, Twyneo |
| Novartis Pharmaceuticals Corporation | $551.60 | 2021-2025 | |
| Janssen Biotech, INC. | $505.81 | 2021-2025 | Tremfya |
| Incyte Corporation | $468.28 | 2021-2025 | Opzelura |
| Genzyme Corporation | $361.79 | 2021-2023 | |
| Ucb, INC. | $327.19 | 2021-2025 | Bimzelx |
| Janssen Scientific Affairs, LLC | $239.10 | 2024-2025 | Tremfya |
| Pfizer INC. | $182.58 | 2021-2025 | |
| Organon LLC | $172.96 | 2025 | Vtama, Nexplanon |
| Amgen INC. | $170.03 | 2023-2024 | Otezla |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $163.32 | 2021-2025 | |
| Vyne Pharmaceuticals INC. | $137.63 | 2021 | |
| Lilly USA, LLC | $106.39 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $89.43 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.64 | 2023 | Spevigo |
| Mayne Pharma Commercial LLC | $42.33 | 2022-2023 | |
| Botanix Sb INC | $35.15 | 2025 | Sofdra |
| Ani Pharmaceuticals, INC. | $28.66 | 2025 | Veregen |
| Organogenesis INC. | $27.77 | 2022 | |
| Boston Scientific Corporation | $22.97 | 2025 | Watchman Flx |
| Sanofi-Aventis U.S. LLC | $20.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexa Thomas Deck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.